Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- ...
Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...
Hosted on MSN25d
Inhibikase Halts Parkinson's Drug Development to Focus on PAHInhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug ...
Jan 29 (Reuters) - Inhibikase Therapeutics (IKT.O), opens new tab said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients ...
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.
H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused ...
Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and Inhibikase Therapeutics, Inc. (IKT) 10-day simple moving average is 2.65. Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and ...
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback